Cargando…

Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans

BACKGROUND: Setipiprant, a tetrahydropyridoindole derivative, is a CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper [Th]-2 cells) antagonist that has the potential to be effective in the treatment of patients with diseases with an allergic etiology, such as allergic rhinitis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoch, Matthias, Wank, Janine, Kluge, Ina, Wagner-Redeker, Winfried, Dingemanse, Jasper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851755/ https://www.ncbi.nlm.nih.gov/pubmed/24214422 http://dx.doi.org/10.1007/s40268-013-0031-7

Ejemplares similares

CRTH2 antagonists in asthma: current perspectives
por: Singh, Dave, et al.
Publicado: (2017)

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies
por: Ratner, Paul, et al.
Publicado: (2017)

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
por: Erpenbeck, Veit J., et al.
Publicado: (2016)

An Investigation of Situational and Dispositional Antecedents of Faking Intentions in Selection Interviews
por: Bill, Benedikt, et al.
Publicado: (2020)

Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
por: Kuna, Piotr, et al.
Publicado: (2016)

CRTH2 expression on T cells in asthma
por: Mutalithas, K, et al.
Publicado: (2010)

CRTH2: a potential target for the treatment of organ fibrosis: CRTH2 is a potential target for organ fibrosis
por: Fan, Sisi, et al.
Publicado: (2022)

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

CRTH2 in Pulmonary Fibrosis: Friend or Foe?
por: He, Chao, et al.
Publicado: (2022)

Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
por: DuBois, Janet, et al.
Publicado: (2021)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

The impact of CRTH2 antagonist OC 000459 on pulmonary function of asthma patients: a meta-analysis of randomized controlled trials
por: Tang, Meng, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

A CRTH2 antagonist, CT-133, suppresses NF-κB signalling to relieve lipopolysaccharide-induced acute lung injury
por: Hussain, Musaddique, et al.
Publicado: (2019)

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
por: Berger, Benjamin, et al.
Publicado: (2023)

The therapeutic potential of CRTH2/DP2 beyond allergy and asthma
por: Jandl, Katharina, et al.
Publicado: (2017)

Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonists in asthma: a systematic review and meta-analysis protocol
por: Liu, Wei, et al.
Publicado: (2018)

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
por: Hsin, Chih-hsuan, et al.
Publicado: (2023)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Biocomparison of Three Formulations of the S1P(1) Receptor Modulator Ponesimod in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2015)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β(2)-agonists in patients with atopic asthma
por: Bateman, Eric D, et al.
Publicado: (2018)

Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D(2)
por: Nagata, Nanae, et al.
Publicado: (2017)

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
por: Dingemanse, Jasper, et al.
Publicado: (2014)

Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
por: Rudulier, Christopher D., et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
por: Juif, Pierre-Eric, et al.
Publicado: (2022)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice
por: Chen, Guilin, et al.
Publicado: (2018)

Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration
por: Hoffmann, Matthew, et al.
Publicado: (2011)

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans
por: Piel, Isabel, et al.
Publicado: (2023)

Cross-talk of PGD(2) receptors: the DP receptor modulates signaling and trafficking of CRTH2
por: Sedej, Miriam, et al.
Publicado: (2010)

Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes
por: Sykes, Lynne, et al.
Publicado: (2012)

CRTH2 promotes endoplasmic reticulum stress‐induced cardiomyocyte apoptosis through m‐calpain
por: Zuo, Shengkai, et al.
Publicado: (2018)

Activation of Th2 cells downregulates CRTh2 through an NFAT1 mediated mechanism
por: MacLean Scott, Emily, et al.
Publicado: (2018)

The CRTh2 polymorphism rs533116 G > A associates with asthma severity in older females
por: Shrestha Palikhe, Nami, et al.
Publicado: (2022)

Over-expression of CRTH2 indicates eosinophilic inflammation and poor prognosis in recurrent nasal polyps
por: Chen, Wenhui, et al.
Publicado: (2022)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
por: Huynh, Christine, et al.
Publicado: (2022)

Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys
por: Banijamali, Ali R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ofofcstdqsg15njt528595coqc